The path towards an HIV vaccine

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Hundreds of Phase I HIV vaccine studies have been conducted since the 1980s, but few advanced to efficacy trials.
• Recent HIV vaccine trials initiated in 2016 and 2017 were halted due to non-efficacy, highlighting persistent challenges.

Purpose of the Study:

• To review the challenges and advancements in HIV vaccine development.
• To explore novel tools and platform technologies for accelerating HIV vaccine strategies.
• To emphasize the role of experimental medicine in guiding early-stage product development with human data.

Main Methods:

• Review of historical HIV vaccine trial data.
• Analysis of recent clinical trial outcomes.
• Discussion of emerging technologies and experimental medicine approaches.

Main Results:

• Limited success in advancing HIV vaccine candidates to late-stage efficacy trials.
• Halt of two recent HIV vaccine trials due to lack of efficacy.
• Identification of new tools and platform technologies for improved vaccine development.

Conclusions:

• The development of a safe, effective, and durable HIV vaccine continues to face significant hurdles.
• Advancements in technology and the integration of early human data through experimental medicine are crucial for accelerating HIV vaccine discovery.
• Future HIV vaccine research must leverage innovative strategies to overcome past challenges.